London-based healthtech startup Little Journey has announced a significant milestone in its mission to transform paediatric care through personalised psychological support. The company has secured £6 million in Series A funding, led by Par Equity , with additional contributions from Mercia Ventures , the NORTHERN POWERHOUSE INVESTMENTS LIMITED Fund, Octopus Ventures , Calm/Storm Ventures, and angel investors.
The funding will be used to scale Little Journey’s operations globally, with a particular focus on the US healthcare market. Early adopters have already shown great interest, and the company aims to extend its transformative support to more children and families worldwide. The investment will also fund product enhancements, including the development of scalable content, interoperability, and data collection capabilities.
Little Journey’s innovative approach to paediatric care addresses key challenges in recruitment, adherence, and trial completion rates in clinical trials. By providing personalised psychological support, the company aims to improve outcomes for paediatric patients globally.
With this new funding, Little Journey is well-positioned to redefine how paediatric clinical trials are conducted and put families at the heart of healthcare.
#HealthTech #PaediatricCare #SeriesAFunding #Innovation #GlobalHealth #Investment #LittleJourney | Chris Evans | Sophie Copley | Paul Atkinson | Robert H. | Paul Munn | Mark Payton – Mercia Asset Management | Simon Rogerson | Chris Hulatt | Guy Myles | Lucanus ⛵️ Polagnoli
